I’m incredibly proud of our BCg team and our remarkable clinical partners. Together, we’ve prepared OraFyl for a focused commercial launch—supported by compelling clinical experience showing enhanced patient outcomes across multiple oral surgical procedures, including gingival recession, tooth extraction and implantation, Black Triangles (interdental papilla reconstruction), and Guided Bone Regeneration (GBR).
Why this moment matters
Innovation in regenerative dentistry only becomes meaningful when it consistently improves patient care at the chairside. Over the past months, our BCg team—working hand‑in‑hand with outstanding clinicians—has advanced OraFyl from concept to clinical reality. The result is a regenerative solution for a set of practical protocols that are intuitive for surgeons and impactful for patients.
“We built OraFyl around what clinicians told us they needed: a reliable, easy‑to‑handle regenerative matrix that integrates into existing “Gold-Standard” regenerative procedures and techniques that deliver clinically visible, patient‑relevant outcomes.” —Dr. Dard
What clinicians are seeing
Across diverse case types and operator styles, our clinical partners report outcomes that matter:
- Gingival recession (root coverage & soft‑tissue quality): OraFyl has been used to support root coverage procedures while aiming to improve soft‑tissue thickness and the quality of keratinized mucosa—key drivers of long‑term stability and esthetics.
- Tooth extraction & implantation: In immediate and delayed pathways, clinicians report favorable socket healing and soft‑tissue architecture around implants, supporting emergence profile development and peri‑implant health.
- Black Triangles / interdental papilla reconstruction: OraFyl has been incorporated into papilla‑focused protocols designed to reduce open embrasures and improve smile esthetics—one of the most visible, patient‑appreciated outcomes.
- Guided Bone Regeneration (GBR) & ridge preservation: Used alongside standard GBR principles, OraFyl has supported soft‑tissue management over grafted sites and has been integrated into alveolar ridge preservation workflows to help maintain ridge form for future implant placement.
While techniques vary by clinician, the themes and observations are consistent: Useability, soft‑tissue quality, and workflow fit. That combination is why our partners are excited—and why we are confident of the initial launch initiatives.
What makes OraFyl different
OraFyl is a next‑generation, acellular, placental‑derived extracellular matrix designed to support the body’s own healing response. In practice, that means:
- Tissue support where it counts: OraFyl is engineered to interface with host tissues in both soft‑ and hard‑tissue procedures.
- Protocol‑friendly handling: From papilla reconstruction to ridge preservation, clinicians can integrate OraFyl without overhauling the steps they already trust.
- Patient‑centric outcomes: Our partners focus on outcomes patients feel and see—reduced open embrasures, improved soft‑tissue contours, and favorable peri‑implant architecture.
Procedural highlights
- Recession Coverage: In combination with established techniques, OraFyl is being used to target soft‑tissue thickness and esthetic blending—two variables that influence long‑term root coverage stability.
- Immediate Implantation: Clinicians report that OraFyl supports soft‑tissue collapse control and emergence shaping—especially valuable in esthetic zones.
- Black Triangles: For selected cases, OraFyl has been incorporated into minimally invasive papilla‑oriented approaches intended to reduce the visual gap and improve smile harmony.
- GBR & Ridge Preservation: OraFyl is used to support flap management over grafted sites and to help maintain ridge form ahead of implant placement.
The people behind the progress
None of this would be possible without our BCg team and our clinical partners—a community of surgeons and researchers who pressure‑test ideas in real‑world settings, share what works (and what doesn’t), and refine protocols with patient outcomes as the north star. Their rigor and candor have been essential in shaping OraFyl into a launch‑ready solution.
“Our partners asked the BCg team for a dependable, evidence‑driven biological regenerative tool that plays nicely with the procedures they already perform. OraFyl is our answer.” —Dr. Dard
What’s next
- Launch & training: As we open access, we’ll provide concise, procedure‑specific playbooks and case examples so teams can get started quickly.
- Ongoing evidence program: We’re committed to continued data generation across indications and to sharing real‑world outcomes as they accumulate.
- Clinical collaboration: If you’re interested in contributing cases or joining our training/learning centers, we’d love to hear from you.
- Purchase orders: Our very own Michael Wilhelm, Founder, EVP of Partnerships is working closely with our manufacturing partner on the company’s initial purchase order for immediate delivery as well as ongoing planning and forecasting on future orders designed to satisfy expected OraFyl adoption rate and demand.
A final word of thanks
To our team at BCg and to our clinical collaborators: thank you. Your expertise, integrity, and relentless focus on patient care have prepared OraFyl for a meaningful commercial debut. I am looking forward to our forthcoming accomplishments together.
Founder, CEO
